Open AccessBeneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome
Author(s) -
Romy Franken,
Alexander W. den Hartog,
Teodora Radonic,
Dimitra Micha,
Alessandra Maugeri,
Fleur S van Dijk,
Hanne MeijersHeijboer,
Janneke Timmermans,
Arthur J. Scholte,
Maarten P. van den Berg,
Maarten Groenink,
Barbara J.M. Mulder,
Aeilko H. Zwinderman,
Vivian de Waard,
Gerard Pals
Publication year - 2015
Publication title -
circulation cardiovascular genetics
Language(s) - English
Resource type - Journals
eISSN - 1942-325X
pISSN - 1942-3268
DOI - 10.1161/circgenetics.114.000950
Subject(s) - marfan syndrome , losartan , medicine , mutation , cardiology , genetics , biology , angiotensin ii , gene , receptor
It has been shown that losartan reduces aortic dilatation in patients with Marfan syndrome. However, treatment response is highly variable. This study investigates losartan effectiveness in genetically classified subgroups.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom